Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic

Mar 06 2018

• By Mandy Jackson

T-cells attacking cancer_1200x675

Related Content

Amgen Will Try To Convince ODAC Of Minimal Disease Endpoint To Show Blincyto's Efficacy

Mar 05 2018

Amgen, Merck To Test New Immunotherapy Combination

Dec 06 2015

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Sep 08 2016

Amgen gains early US win for BiTE antibody Blincyto

Dec 04 2014

Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Jan 27 2012

Related Companies

Amgen, Inc.

Micromet, Inc.

Merck & Co., Inc.

Additional Topics

ImmunoOncology Companies Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window